Dividend Adjusted Return
Nov 13, 2025 - Nov 13, 2026AMGN 465.67 (+42.3%)
Healthcare 347.93 (+24.3%)
S&P 500 7561.67 (+11.6%)






Stock Rover estimates Amgen’s intrinsic (fair) value at $420.91, against a recent price of $465.67, a margin of safety of -10%. Quantitative scores (0–100): Value 69, Quality 89, Growth 90, Sentiment 58. Analyst consensus: Buy.







Fair Value | $420.91 | |
Margin of Safety | -10% |
Value Score 69 Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks | Quality Score 89 Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics. |
Growth Score 90 Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks. | Sentiment Score 58 Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals. |
| AMGN | Industry | S&P 500 | |
|---|---|---|---|
| Value Score | 69 | 69 | 68 |
| Price / Earnings | 27.0 | 34.7 | 24.9 |
| Price / Sales | 6.5 | 5.3 | 3.5 |
| Price / Free Cash Flow | 26.5 | 28.8 | 35.4 |
| Price / Book | 17.6 | 7.5 | 5.6 |
| Price / Tangible Book | - | - | 361.3 |
| EV / EBITDA | 16.1 | 23.6 | 18.1 |
| EPS Predict. Pctl. | 81 | 72 | 71 |
| Piotroski F Score | 8 | 6 | 7 |
| 5‑Year P/E Range | 14.9 56.4 |
| 5‑Year P/B Range | 13.7 147.6 |
| 5‑Year P/S Range | 4.2 6.7 |
| AMGN | Industry | S&P 500 | |
|---|---|---|---|
| Growth Score | 90 | 69 | 79 |
| Sales Growth | |||
| Sales Growth Next Year | 4.6% | 16.7% | 20.6% |
| Sales 1‑Year Chg (%) | 8.2% | 17.5% | 19.3% |
| Sales 3‑Year Avg (%) | 13.2% | 17.0% | 14.8% |
| Sales 5‑Year Avg (%) | 8.6% | 9.4% | 13.3% |
| EPS Growth | |||
| Next Yr. Growth Est. | 6.4% | 35.1% | 15.4% |
| EPS 1‑Year Chg (%) | 33.4% | 26.4% | 44.9% |
| EPS 3‑Year Avg (%) | 7.0% | 37.9% | 20.4% |
| EPS 5‑Year Avg (%) | 12.2% | 23.2% | 15.4% |






MRK | Merck & Co | $364,264 | 149.3 | 2.3% | 4.1% | 63.7% | 1% | 61 | 77 | 64 |
NVS | Novartis | $303,124 | 30.6 | 3.0% | 12.7% | 25.4% | 2% | 72 | 80 | 91 |
AZN | AstraZeneca | $286,066 | 26.1 | 1.7% | 18.4% | 5.7% | -2% | 64 | 94 | 94 |
AMGN | Amgen | $251,886 | 27.0 | 2.2% | 12.8% | 42.4% | -10% | 69 | 90 | 89 |
GILD | Gilead Sciences | $208,476 | - | 2.0% | 13.6% | 37.6% | -21% | 61 | 60 | 77 |
NVO | Novo Nordisk | $183,519 | 10.5 | 4.3% | 9.4% | -11.2% | -5% | 85 | 77 | 83 |
PFE | Pfizer | $164,668 | 41.3 | 6.0% | 1.8% | 17.8% | 27% | 72 | 44 | 83 |
BMY | Bristol-Myers Squibb | $129,656 | 14.1 | 4.0% | 11.9% | 36.2% | 27% | 79 | 56 | 91 |
SNY | Sanofi | $116,134 | 24.1 | 5.0% | 23.6% | -2.5% | 16% | 87 | 81 | 89 |
GSK | GSK | $101,125 | 17.6 | 3.6% | 9.0% | 8.5% | 30% | 82 | 81 | 90 |
BIIB | Biogen | $37,457 | 109.7 | - | 10.7% | 53.8% | -2% | 68 | 63 | 74 |
GRFS | Grifols | $5,917 | 10.5 | 1.2% | 21.3% | 1.5% | 22% | 96 | 74 | 64 |
| AMGN | Industry | S&P 500 | |
|---|---|---|---|
| Quality Score | 89 | 79 | 77 |
| Gross Margin | 70.9% | 73.2% | 33.2% |
| Operating Margin | 32.4% | 27.8% | 17.4% |
| Net Margin | 24.1% | 15.2% | 14.2% |
| Return on Assets | 10.1% | 10.5% | 14.1% |
| Return on Equity | 65.4% | 34.8% | 37.7% |
| ROIC | 15.7% | 22.4% | 24.1% |
| AMGN | Industry | S&P 500 | |
|---|---|---|---|
| Sentiment Score | 58 | 65 | 71 |
| 5‑Day Return | 1.1% | 2.6% | 2.5% |
| 1‑Month Return | 12.8% | 13.7% | -3.1% |
| YTD Return | 45.2% | 26.1% | 11.3% |
| 1‑Year Return | 42.4% | 32.2% | 13.4% |
| 3‑Year Return | 91.0% | 73.8% | 77.8% |
| 5‑Year Return | 157.4% | 84.6% | 72.7% |
| Beta 1‑Year | 0.49 | 0.19 | 1.00 |






| AMGN | Industry | |
|---|---|---|
| Forward Dividend Yield | 2.2% | 2.0% |
| Payout Ratio | 57.2% | 42.7% |
| TTM Yield | 2.1% | - |
| Fwd. Div. Per Share | $10.08 | $4.54 |
| Div. 1Y Chg (%) | 5.9% | - |
| Div. 3Y Avg (%) | 5.8% | - |
| Div. 5Y Avg (%) | 7.4% | - |
| Cons. Growth Years | 10+ | - |
| Div. Coverage Ratio | 1.7 | 1.4 |
| Current Ratio | 1.5 |
| Quick Ratio | 1.2 |
| Price | $465.67 |
| Net Cash Per Share | -$75.87 |
| Equity Per Share | $26.53 |
| Debt / Equity | 3.8 |
| Solvency Ratio | 19% |
| Interest Coverage | 5.2 |
| Short % of Float | 2.3% |
| Altman Z‑Score | 2.5 |
| Current Quarter EPS | |
|---|---|
# Up Last 30 days | 7.00 |
# Down Last 30 days | 5.00 |
Mean Estimate | 5.65 |
% Change (30 Days) | -2.31% |
| Next Quarter EPS | |
|---|---|
# Up Last 30 days | 3.00 |
# Down Last 30 days | 1.00 |
Mean Estimate | 5.70 |
% Change (30 Days) | 1.73% |
| Cur Qtr | Next Qtr | Cur Year | Next Year | |
|---|---|---|---|---|
| Latest | $5.65 | $5.70 | $23.52 | $25.03 |
| 30 Days Ago | $5.78 | $5.61 | $23.02 | $24.48 |
| 90 Days Ago | $5.81 | $5.59 | $22.99 | $24.28 |
| % Change (90 Days) | -2.8% | 1.9% | 2.3% | 3.1% |
| Surprise Type | Amount | Percent |
|---|---|---|
| Positive Quarters (> 2%) | 10 | 83.3% |
| Negative Quarters (< 2%) | 0 | - |
| In-Line Quarters (within 2%) | 2 | 16.7% |
| Surprise Type | Announce Date | Period End Date | Actual EPS | Est. EPS | Surprise (%) |
|---|---|---|---|---|---|
| Positive | 11/03/26 | 09/30/26 | $6.45 | $5.74 | 12.4% |
| Positive | 08/04/26 | 06/30/26 | $6.29 | $5.60 | 12.3% |
| Positive | 04/30/26 | 03/31/26 | $5.15 | $4.73 | 8.9% |
| Positive | 02/03/26 | 12/31/25 | $5.29 | $4.76 | 11.1% |
| Positive | 10/29/25 | 09/30/25 | $5.64 | $5.00 | 12.8% |
| Positive | 08/05/25 | 06/30/25 | $6.02 | $5.26 | 14.4% |
| AMGN | Industry | S&P 500 | |
|---|---|---|---|
| Best Monthly Return (5Y) | 17.3% | 13.1% | 9.6% |
| Worst Monthly Return (5Y) | -15.6% | -6.8% | -9.6% |
| Beta 1‑Year | 0.49 | 0.19 | 1.00 |
| Volatility 1‑Year | 0.28 | 0.17 | 0.13 |
| Volatility 1Y Pctl. | 27 | - | - |
| Max Drawdown 1‑Year | -16.6% | -19.7% | -8.8% |
| Max Drawdown 3‑Year | -22.7% | -27.6% | -18.7% |
| Max Drawdown 5‑Year | -24.9% | -30.4% | -24.6% |











AZN | AstraZeneca | 90 | 6.7% | 23.5% | 6.3% | 7.3% | 11.5% | 13.7% |
AMGN | Amgen | 80 | 8.5% | 19.4% | 4.6% | 8.2% | 13.2% | 8.6% |
NVO | Novo Nordisk | 66 | 5.6% | -15.8% | 1.3% | 5.7% | 15.9% | 19.9% |
GILD | Gilead Sciences | 50 | 6.8% | -20.2% | 7.1% | 6.5% | 4.2% | 2.4% |
PFE | Pfizer | 12 | -0.4% | -9.7% | -3.6% | 1.3% | -2.8% | -1.6% |
NVO | Novo Nordisk | 78 | 10.5 | 12.4 | 0.5 | 3.6 | 5.6 | 9.0 56.8 |
AZN | AstraZeneca | 73 | 26.1 | 16.3 | 0.6 | 4.6 | 5.5 | 22.0 - |
AMGN | Amgen | 39 | 27.0 | 18.6 | 2.2 | 6.5 | 17.6 | 14.9 56.4 |
PFE | Pfizer | 30 | 41.3 | 9.8 | - | 2.6 | 1.9 | 6.3 - |
GILD | Gilead Sciences | 6 | - | 16.6 | - | 6.8 | 16.0 | 9.9 - |
NVO | Novo Nordisk | 91 | 80.8% | 42.4% | 33.9% | 52.0% 90.3% | 20.1% 30.9% |
AZN | AstraZeneca | 83 | 81.9% | 23.5% | 17.7% | -3.5% 21.9% | -1.3% 9.5% |
AMGN | Amgen | 80 | 70.9% | 32.4% | 24.1% | 52.8% 624.8% | 3.4% 11.8% |
GILD | Gilead Sciences | 59 | 79.9% | 37.8% | -12.5% | -29.6% 39.2% | -7.0% 16.1% |
PFE | Pfizer | 56 | 73.4% | 26.1% | 6.3% | -3.0% 33.6% | -1.2% 16.5% |
AZN | AstraZeneca | 77 | 0.7 | 8.4 | 0.8 | 49.5% | 29% | 0.2% |
PFE | Pfizer | 67 | 0.7 | 2.6 | 1.1 | 57.4% | 11% | 2.4% |
NVO | Novo Nordisk | 54 | 0.6 | - | 0.5 | 18.7% | 38% | 1.2% |
AMGN | Amgen | 49 | 3.8 | 5.2 | 1.2 | 39.8% | 19% | 2.3% |
GILD | Gilead Sciences | 39 | 2.0 | -1.5 | 1.2 | 42.3% | -3% | 1.7% |
NVO | Novo Nordisk | 78 | 4.3% | 4.3% | $41.63 | $1.80 | 8 | 45.3% |
AMGN | Amgen | 55 | 2.2% | 2.1% | $465.67 | $10.08 | 10+ | 57.2% |
PFE | Pfizer | 49 | 6.0% | 6.0% | $28.89 | $1.72 | 10+ | 242.3% |
AZN | AstraZeneca | 41 | 1.7% | 1.7% | $184.45 | $3.20 | 5 | 45.0% |
GILD | Gilead Sciences | 29 | 2.0% | 1.9% | $168.08 | $3.28 | 10+ | - |
AMGN | Amgen | 98 | 12.8% | 12.1% | 40.3% | 45.2% | 42.4% | 0.49 | 0.28 | 96.2% |
GILD | Gilead Sciences | 98 | 13.6% | 22.4% | 27.9% | 39.4% | 37.6% | 0.39 | 0.27 | 95.2% |
PFE | Pfizer | 87 | 1.8% | 7.8% | 13.2% | 22.0% | 17.8% | 0.26 | 0.21 | 91.9% |
AZN | AstraZeneca | 86 | 18.4% | 17.3% | -1.1% | 6.9% | 5.7% | 0.17 | 0.30 | 86.7% |
NVO | Novo Nordisk | 58 | 9.4% | -9.8% | -10.4% | -14.2% | -11.2% | 0.95 | 0.45 | 64.9% |





2026 Dividends | $10.08 |
11/20/26 | 12/11/26 | Regular | $2.52 |
08/21/26 | 09/11/26 | Regular | $2.52 |
05/15/26 | 06/05/26 | Regular | $2.52 |
02/13/26 | 03/06/26 | Regular | $2.52 |
2025 Dividends | $9.52 |
11/21/25 | 12/12/25 | Regular | $2.38 |
08/22/25 | 09/12/25 | Regular | $2.38 |
05/16/25 | 06/06/25 | Regular | $2.38 |
02/14/25 | 03/07/25 | Regular | $2.38 |
2024 Dividends | $9.00 |
11/18/24 | 12/09/24 | Regular | $2.25 |
08/16/24 | 09/06/24 | Regular | $2.25 |
05/16/24 | 06/07/24 | Regular | $2.25 |
02/15/24 | 03/07/24 | Regular | $2.25 |
2023 Dividends | $8.52 |
11/16/23 | 12/08/23 | Regular | $2.13 |
08/17/23 | 09/08/23 | Regular | $2.13 |
05/17/23 | 06/08/23 | Regular | $2.13 |
02/14/23 | 03/08/23 | Regular | $2.13 |
2022 Dividends | $7.76 |
11/16/22 | 12/08/22 | Regular | $1.94 |
08/17/22 | 09/08/22 | Regular | $1.94 |
05/16/22 | 06/08/22 | Regular | $1.94 |
Ex-Dividend Date | 11/20/26 |
Payment Date | 12/11/26 |
Amount | $2.52 |
Type | Regular |
Regular Dividend | $2.52 |
Forward Dividend Rate | $10.08 |
Forward Dividend Yield | 2.2% |
Trailing 12 Months Dividends | $9.94 |
Trailing 12 Months Yield | 2.1% |
Payout Ratio | 57.2 |
Dividend Coverage Ratio | 1.7 |
Consecutive Growth Years | 10+ |
3 Year Growth Rate | 5.8% |
5 Year Growth Rate | 7.4% |
10 Year Growth Rate | 9.7% |
Price / Earnings | 27.0 | 27.5 | 51.8 | 18.0 | 24.2 |
Price / Cash Flow | 21.1 | 13.9 | 22.4 | 13.6 | 15.8 |
Price / Book | 17.6 | 24.4 | 27.3 | 21.0 | 63.0 |
Price / Tangible Book | - | - | - | - | - |
Price / Sales | 6.5 | 5.2 | 5.3 | 5.4 | 6.0 |
EV / EBITDA | 16.1 | 13.9 | 16.0 | 11.5 | 14.6 |
Forward Dividend Yield | 2.2% | 2.8% | 3.0% | 3.2% | 2.7% |
Shareholder Yield | 2.2% | 2.8% | 3.0% | 3.2% | 7.9% |
Gross Margin | 70.9% | 66.2% | 60.5% | 73.6% | 75.8% |
Net Margin | 24.1% | 19.5% | 13.0% | 28.2% | 26.0% |
Return on Assets | 10.1% | 7.8% | 4.6% | 9.5% | 11.1% |
Return on Equity | 65.4% | 72.8% | 56.2% | 98.8% | 187.1% |
ROIC | 15.7% | 11.5% | 8.3% | 11.2% | 20.1% |
Additional data provided by Zacks, Intrinio, Quandl, Yodlee, IEX Cloud
AMGN has outperformed its sector by 18.1% in the past year.
The Healthcare sector has outperformed the market by 12.7% in the past year.